ARS Pharmaceuticals, Inc.
SPRY
$9.84
$0.292.98%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -63.00% | -7.08% | 68.51% | 114.71% | 20.32% |
| Total Depreciation and Amortization | 1,479.03% | 882.26% | 443.75% | 8.22% | -17.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 230.65% | 215.86% | 182.90% | 204.99% | -35.76% |
| Change in Net Operating Assets | -1,102.43% | -410.84% | -101.00% | 75.42% | 77.97% |
| Cash from Operations | -86.16% | -19.57% | 61.75% | 122.86% | 26.46% |
| Capital Expenditure | -277.06% | -700.00% | -778.46% | -221.71% | 56.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -413.08% | 83.87% | -526.89% | -21.30% | 119.36% |
| Cash from Investing | -418.49% | 82.50% | -532.25% | -21.70% | 119.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 65.27% | 59.68% | -40.34% | -56.28% | -38.85% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5,203.62% | 2,025.76% | 1,148.13% | 949.41% | -98.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 195.33% | 118.10% | 49.33% | 85.56% | -189.94% |